Interleukin Genetics, Inc. (OTCQB: ILIU), which is pioneering the use of genetic information for the prevention and improved management of certain chronic conditions of aging, today announced that it has entered into a three year Preferred Participation Agreement with Renaissance Health Service Corporation, and certain of its affiliates and subsidiaries, (collectively “RHSC”). Pursuant to the Agreement, RHSC has agreed to reimburse Interleukin a fixed price for each PST ® genetic test that it processes for a customer of RHSC.
Interleukin’s proprietary PST ® genetic risk panel for periodontal disease severity and tooth loss susceptibility addresses the need to identify individuals who are at greater risk of severe periodontitis, a primary cause of tooth loss.
“We are encouraged by RHSC’s efforts to advance personalized health in dentistry through the use of our unique periodontal susceptibility risk test, PST ®,” said Kenneth S. Kornman, CEO, Interleukin Genetics.
About Renaissance Health Service CorporationRenaissance Health Service Corporation (RHSC) is the parent organization for a family of companies that are leaders in the dental insurance industry. RHSC companies are among the largest and oldest group of dental benefit providers in the United States, covering 11 million people and paying out nearly $3 billion in dental benefits in 2012. Currently, the companies employ approximately 1,200 people, who are located in Indianapolis, Indiana; Sherwood and Little Rock, Arkansas; Louisville, Kentucky; Okemos and Farmington Hills, Michigan; Albuquerque, New Mexico; Raleigh and Charlotte, North Carolina; Columbus and Cleveland, Ohio; and Nashville, Knoxville, and Memphis, Tennessee. About Interleukin Genetics Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health ® and PST ® brands. The products empower individuals to prevent certain chronic conditions and manage their existing health and wellness through genetic-based insights with actionable guidance. Interleukin Genetics leverages its research, intellectual property and genetic panel development expertise in metabolism and inflammation to facilitate the emerging personalized healthcare market. The Company markets its tests through partnerships with health and wellness companies, healthcare professionals and other distribution channels. Interleukin Genetics’ flagship products include its proprietary PST ® genetic risk panel for periodontal disease and tooth loss susceptibility sold through dentists and the Inherent Health Weight Management Genetic Test that identifies the most effective diet and exercise program for an individual based on genetics. Interleukin Genetics is headquartered in Waltham, Mass. and operates an on-site, state-of-the-art DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit http://www.ilgenetics.com. Certain statements contained herein are “forward-looking” statements. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, risks related to the adequacy of the Company’s capital resources and the need for additional funding, that the offering of dental plans by RHSC affiliates that include the PST ® test will be delayed significantly, that RHSC affiliates may not be successful in developing or marketing such dental plans, and that such dental plans may not be accepted by dental customers, as well as the risks and uncertainties described in the Company’s annual report on Form 10-K for the year ended December 31, 2011 and other filings with the Securities and Exchange Commission. The Company disclaims any obligation or intention to update these forward-looking statements.